ACHL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
Dagens volum	185 038
Gjennomsnittsvolum	721 446
Markedsverdi	33.02M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0.00400 (0.50%)

Volum Korrelasjon

Lang: -0.15 (neutral)

Kort: -0.01 (neutral)

Signal:(37.945) Neutral

Achilles Therapeutics plc Korrelasjon

10 Mest positive korrelasjoner
STER	0.94
SVAC	0.939
AGLE	0.938
ELEV	0.925
ALZN	0.922
GANX	0.922
TSVT	0.918
PAIC	0.913
SEDG	0.912
ALGT	0.911

10 Mest negative korrelasjoner
TSBK	-0.92
BLTE	-0.918
NETE	-0.912
MITA	-0.911
FANH	-0.906
SGII	-0.905
LOPE	-0.901
CHPM	-0.899
MTSI	-0.898
LWAC	-0.897

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Achilles Therapeutics plc Korrelasjon - Valuta/Råvare

-0.08
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.49
( neutral )

Achilles Therapeutics plc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
Omsetning:	$0
Bruttogevinst:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
Omsetning:	$0
Bruttogevinst:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Sanntidsoppdatering for Achilles Therapeutics plc [ACHL]

Upcoming Earnings Alert